Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 480

1.

Transrenal Ureteral Occlusion for Palliation of Refractory Urine Leaks Using Vascular Plugs and Liquid Ethylene Vinyl Alcohol.

Jalaeian H, Hicks RJ, Hartnell GG, Janne d'Othée B.

J Vasc Interv Radiol. 2019 Sep 14. pii: S1051-0443(19)30423-3. doi: 10.1016/j.jvir.2019.04.029. [Epub ahead of print]

PMID:
31530488
2.

Unmet needs in the international neuroendocrine tumor (NET) community: assessment of major gaps from the perspective of patients, patient advocates and NET healthcare professionals.

Leyden S, Kolarova T, Bouvier C, Caplin M, Conroy S, Davies P, Dureja S, Falconi M, Ferolla P, Fisher G, Goldstein G, Hicks RJ, Lawrence B, Majima Y, Metz DC, O'Toole D, Ruszniewski P, Wiedenmann B, Hollander R; International Neuroendocrine Cancer Alliance (INCA).

Int J Cancer. 2019 Sep 11. doi: 10.1002/ijc.32678. [Epub ahead of print]

PMID:
31509608
3.

Peptide Receptor Radiotherapy: Current Approaches and Future Directions.

Kong G, Hicks RJ.

Curr Treat Options Oncol. 2019 Aug 29;20(10):77. doi: 10.1007/s11864-019-0677-7. Review.

PMID:
31468210
4.

EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT).

Kratochwil C, Fendler WP, Eiber M, Baum R, Bozkurt MF, Czernin J, Delgado Bolton RC, Ezziddin S, Forrer F, Hicks RJ, Hope TA, Kabasakal L, Konijnenberg M, Kopka K, Lassmann M, Mottaghy FM, Oyen W, Rahbar K, Schöder H, Virgolini I, Wester HJ, Bodei L, Fanti S, Haberkorn U, Herrmann K.

Eur J Nucl Med Mol Imaging. 2019 Aug 22. doi: 10.1007/s00259-019-04485-3. [Epub ahead of print]

PMID:
31440799
5.

A Bivalent Inhibitor of Prostate Specific Membrane Antigen Radiolabeled with Copper-64 with High Tumor Uptake and Retention.

Zia NA, Cullinane C, Van Zuylekom JK, Waldeck K, McInnes LE, Buncic G, Haskali MB, Roselt PD, Hicks RJ, Donnelly PS.

Angew Chem Int Ed Engl. 2019 Oct 14;58(42):14991-14994. doi: 10.1002/anie.201908964. Epub 2019 Sep 5.

PMID:
31437347
6.

How we read: the combined use of MRI and novel PET tracers for the characterisation and treatment planning of masses in neuro-oncology.

Lasocki A, Hicks RJ.

Cancer Imaging. 2019 Aug 19;19(1):57. doi: 10.1186/s40644-019-0241-5. Review.

7.

Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for 177Lu-labelled PSMA Radioligand Therapy.

Thang SP, Violet J, Sandhu S, Iravani A, Akhurst T, Kong G, Ravi Kumar A, Murphy DG, Williams SG, Hicks RJ, Hofman MS.

Eur Urol Oncol. 2018 Dec 13. pii: S2588-9311(18)30205-0. doi: 10.1016/j.euo.2018.11.007. [Epub ahead of print]

PMID:
31412006
8.

Early Outcomes of Surgery for Carcinoid Heart Disease.

Yong MS, Kong G, Ludhani P, Michael M, Morgan J, Hofman MS, Hicks RJ, Larobina M.

Heart Lung Circ. 2019 Jun 12. pii: S1443-9506(19)30606-7. doi: 10.1016/j.hlc.2019.05.183. [Epub ahead of print]

PMID:
31383543
9.

Characterizing high-grade serous papillary carcinoma of tunica vaginalis.

Qu LG, Teh J, Mitchell C, Gyorki DE, Hicks RJ, Murphy DG.

Urol Case Rep. 2019 Jun 21;26:100949. doi: 10.1016/j.eucr.2019.100949. eCollection 2019 Sep.

10.

European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma.

Taïeb D, Hicks RJ, Hindié E, Guillet BA, Avram A, Ghedini P, Timmers HJ, Scott AT, Elojeimy S, Rubello D, Virgolini IJ, Fanti S, Balogova S, Pandit-Taskar N, Pacak K.

Eur J Nucl Med Mol Imaging. 2019 Sep;46(10):2112-2137. doi: 10.1007/s00259-019-04398-1. Epub 2019 Jun 29.

PMID:
31254038
11.

Molecular Imaging of Recurrent and Metastatic Prostate Cancer.

Ware RE, Williams S, Hicks RJ.

Semin Nucl Med. 2019 Jul;49(4):280-293. doi: 10.1053/j.semnuclmed.2019.02.005. Epub 2019 Mar 21. Review.

PMID:
31227051
12.

PET-detected pneumonitis following curative-intent chemoradiation in non-small cell lung cancer (NSCLC): recognizing patterns and assessing the impact on the predictive ability of FDG-PET/CT response assessment.

Iravani A, Turgeon GA, Akhurst T, Callahan JW, Bressel M, Everitt SJ, Siva S, Hofman MS, Hicks RJ, Ball DL, Mac Manus MP.

Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1869-1877. doi: 10.1007/s00259-019-04388-3. Epub 2019 Jun 12.

PMID:
31190177
13.

Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series.

Goncalves I, Burbury K, Michael M, Iravani A, Ravi Kumar AS, Akhurst T, Tiong IS, Blombery P, Hofman MS, Westerman D, Hicks RJ, Kong G.

Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1902-1910. doi: 10.1007/s00259-019-04389-2. Epub 2019 Jun 11.

PMID:
31187162
14.

The role of 18F-FDG-PET/CT in evaluating retroperitoneal masses -Keeping your eye on the ball!

Hung TJ, McLean L, Mitchell C, Pascoe C, Lawrentschuk N, Murphy DG, Iravani A, Singh D, Hofman MS, Zidan L, Akhurst T, Lewin J, Hicks RJ.

Cancer Imaging. 2019 May 29;19(1):28. doi: 10.1186/s40644-019-0217-5.

15.

Going nuclear: it is time to embed the nuclear medicine physician in the prostate cancer multidisciplinary team.

Murphy DG, Hofman MS, Azad A, Violet J, Hicks RJ, Lawrentschuk N.

BJU Int. 2019 May 24. doi: 10.1111/bju.14814. [Epub ahead of print] No abstract available.

PMID:
31127664
16.

Intra-individual comparison of 68Ga-PSMA-11 and 18F-DCFPyL normal-organ biodistribution.

Ferreira G, Iravani A, Hofman MS, Hicks RJ.

Cancer Imaging. 2019 May 15;19(1):23. doi: 10.1186/s40644-019-0211-y.

17.

Advancing Biomarker Development Through Convergent Engagement: Summary Report of the 2nd International Danube Symposium on Biomarker Development, Molecular Imaging and Applied Diagnostics; March 14-16, 2018; Vienna, Austria.

Lim MS, Beyer T, Babayan A, Bergmann M, Brehme M, Buyx A, Czernin J, Egger G, Elenitoba-Johnson KSJ, Gückel B, Jačan A, Haslacher H, Hicks RJ, Kenner L, Langanke M, Mitterhauser M, Pichler BJ, Salih HR, Schibli R, Schulz S, Simecek J, Simon J, Soares MO, Stelzl U, Wadsak W, Zatloukal K, Zeitlinger M, Hacker M.

Mol Imaging Biol. 2019 May 2. doi: 10.1007/s11307-019-01361-2. [Epub ahead of print]

PMID:
31049831
18.

Independent and incremental value of ventilation/perfusion PET/CT and CT pulmonary angiography for pulmonary embolism diagnosis: results of the PECAN pilot study.

Le Roux PY, Iravani A, Callahan J, Burbury K, Eu P, Steinfort DP, Lau E, Woon B, Salaun PY, Hicks RJ, Hofman MS.

Eur J Nucl Med Mol Imaging. 2019 Jul;46(8):1596-1604. doi: 10.1007/s00259-019-04338-z. Epub 2019 May 1.

PMID:
31044265
19.

The Role of 68Ga-DOTA-Octreotate PET/CT in Follow-Up of SDH-Associated Pheochromocytoma and Paraganglioma.

Kong G, Schenberg T, Yates CJ, Trainer A, Sachithanandan N, Iravani A, Ravi Kumar A, Hofman MS, Akhurst T, Michael M, Hicks RJ.

J Clin Endocrinol Metab. 2019 Nov 1;104(11):5091-5099. doi: 10.1210/jc.2019-00018.

PMID:
30977831
20.

FDG-PET/CT in managing infection in patients with hematological malignancy: clinician knowledge and experience in Australia.

Douglas AP, Thursky KA, Worth LJ, Harrison SJ, Hicks RJ, Slavin MA.

Leuk Lymphoma. 2019 Oct;60(10):2471-2476. doi: 10.1080/10428194.2019.1590571. Epub 2019 Apr 5.

PMID:
30947578
21.

CAPTEM in Metastatic Well-Differentiated Intermediate to High Grade Neuroendocrine Tumors: A Single Centre Experience.

Sahu A, Jefford M, Lai-Kwon J, Thai A, Hicks RJ, Michael M.

J Oncol. 2019 Feb 20;2019:9032753. doi: 10.1155/2019/9032753. eCollection 2019.

22.

The Contribution of Multiparametric Pelvic and Whole-Body MRI to Interpretation of 18F-Fluoromethylcholine or 68Ga-HBED-CC PSMA-11 PET/CT in Patients with Biochemical Failure After Radical Prostatectomy.

Metser U, Chua S, Ho B, Punwani S, Johnston E, Pouliot F, Tau N, Hawsawy A, Anconina R, Bauman G, Hicks RJ, Weickhardt A, Davis ID, Pond G, Scott AM, Tunariu N, Sidhu H, Emmett L.

J Nucl Med. 2019 Sep;60(9):1253-1258. doi: 10.2967/jnumed.118.225185. Epub 2019 Mar 22.

PMID:
30902875
23.

Modification of Biodistribution and Brain Uptake of Copper Bis(thiosemicarbazonato) Complexes by the Incorporation of Amine and Polyamine Functional Groups.

Paterson BM, Cullinane C, Crouch PJ, White AR, Barnham KJ, Roselt PD, Noonan W, Binns D, Hicks RJ, Donnelly PS.

Inorg Chem. 2019 Apr 1;58(7):4540-4552. doi: 10.1021/acs.inorgchem.9b00117. Epub 2019 Mar 14.

PMID:
30869878
24.

Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.

Tan L, Sandhu S, Lee RJ, Li J, Callahan J, Ftouni S, Dhomen N, Middlehurst P, Wallace A, Raleigh J, Hatzimihalis A, Henderson MA, Shackleton M, Haydon A, Mar V, Gyorki DE, Oudit D, Dawson MA, Hicks RJ, Lorigan P, McArthur GA, Marais R, Wong SQ, Dawson SJ.

Ann Oncol. 2019 May 1;30(5):804-814. doi: 10.1093/annonc/mdz048.

PMID:
30838379
25.

Personalised insulin calculator enables safe and effective correction of hyperglycaemia prior to FDG PET/CT.

Pattison DA, MacFarlane LL, Callahan J, Kane EL, Akhurst T, Hicks RJ.

EJNMMI Res. 2019 Feb 8;9(1):15. doi: 10.1186/s13550-019-0480-2.

26.

2020 vision or myopia? A personal perspective on the future of cancer imaging and an introduction to the sequels to the "How I Read Series".

Hicks RJ.

Cancer Imaging. 2019 Feb 6;19(1):7. doi: 10.1186/s40644-019-0194-8. No abstract available.

27.

Metabolic patterns and seizure outcomes following anterior temporal lobectomy.

Cahill V, Sinclair B, Malpas CB, McIntosh AM, Chen Z, Vivash LE, O'Shea MF, Wilson SJ, Desmond PM, Berlangieri SU, Hicks RJ, Rowe CC, Morokoff AP, King JA, Fabinyi GC, Kaye AH, Kwan P, Berkovic SF, O'Brien TJ.

Ann Neurol. 2019 Feb;85(2):241-250. doi: 10.1002/ana.25405. Epub 2019 Jan 17.

PMID:
30609109
28.

PET/CT Lung Ventilation and Perfusion Scanning using Galligas and Gallium-68-MAA.

Le Roux PY, Hicks RJ, Siva S, Hofman MS.

Semin Nucl Med. 2019 Jan;49(1):71-81. doi: 10.1053/j.semnuclmed.2018.10.013. Epub 2018 Nov 17. Review.

PMID:
30545520
29.

Voxel-wise correlation of positron emission tomography/computed tomography with multiparametric magnetic resonance imaging and histology of the prostate using a sophisticated registration framework.

Reynolds HM, Williams S, Jackson P, Mitchell C, Hofman MS, Hicks RJ, Murphy DG, Haworth A.

BJU Int. 2019 Jun;123(6):1020-1030. doi: 10.1111/bju.14648. Epub 2019 Jan 28.

PMID:
30536698
30.

Consensus on molecular imaging and theranostics in prostate cancer.

Fanti S, Minozzi S, Antoch G, Banks I, Briganti A, Carrio I, Chiti A, Clarke N, Eiber M, De Bono J, Fizazi K, Gillessen S, Gledhill S, Haberkorn U, Herrmann K, Hicks RJ, Lecouvet F, Montironi R, Ost P, O'Sullivan JM, Padhani AR, Schalken JA, Scher HI, Tombal B, van Moorselaar RJA, Van Poppel H, Vargas HA, Walz J, Weber WA, Wester HJ, Oyen WJG.

Lancet Oncol. 2018 Dec;19(12):e696-e708. doi: 10.1016/S1470-2045(18)30604-1.

PMID:
30507436
31.

Prospective, Multisite, International Comparison of 18F-Fluoromethylcholine PET/CT, Multiparametric MRI, and 68Ga-HBED-CC PSMA-11 PET/CT in Men with High-Risk Features and Biochemical Failure After Radical Prostatectomy: Clinical Performance and Patient Outcomes.

Emmett L, Metser U, Bauman G, Hicks RJ, Weickhardt A, Davis ID, Punwani S, Pond G, Chua S, Ho B, Johnston E, Pouliot F, Scott AM.

J Nucl Med. 2019 Jun;60(6):794-800. doi: 10.2967/jnumed.118.220103. Epub 2018 Nov 15.

PMID:
30442757
32.

64Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy.

Hicks RJ, Jackson P, Kong G, Ware RE, Hofman MS, Pattison DA, Akhurst TA, Drummond E, Roselt P, Callahan J, Price R, Jeffery CM, Hong E, Noonan W, Herschtal A, Hicks LJ, Hedt A, Harris M, Paterson BM, Donnelly PS.

J Nucl Med. 2019 Jun;60(6):777-785. doi: 10.2967/jnumed.118.217745. Epub 2018 Nov 15.

PMID:
30442752
33.

Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series.

Mitchell EL, Lau PKH, Khoo C, Liew D, Leung J, Liu B, Rischin A, Frauman AG, Kee D, Smith K, Brady B, Rischin D, Gibson A, Mileshkin L, Klein O, Weickhardt A, Arulananda S, Shackleton M, McArthur G, Östör A, Cebon J, Solomon B, Buchanan RR, Wicks IP, Lo S, Hicks RJ, Sandhu S.

Eur J Cancer. 2018 Dec;105:88-102. doi: 10.1016/j.ejca.2018.09.027. Epub 2018 Nov 13.

PMID:
30439628
34.

An International Survey on Clinical Reporting of PET/CT Examinations: A Starting Point for Cross-Specialty Engagement.

Freudenberg LS, Hicks RJ, Beyer T.

J Nucl Med. 2019 Apr;60(4):480-485. doi: 10.2967/jnumed.118.218073. Epub 2018 Nov 2.

PMID:
30389815
35.

Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN).

Kong G, Grozinsky-Glasberg S, Hofman MS, Akhurst T, Meirovitz A, Maimon O, Krausz Y, Godefroy J, Michael M, Gross DJ, Hicks RJ.

Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):718-727. doi: 10.1007/s00259-018-4196-8. Epub 2018 Oct 20.

PMID:
30343432
36.

FDG PET/CT for assessing tumour response to immunotherapy : Report on the EANM symposium on immune modulation and recent review of the literature.

Aide N, Hicks RJ, Le Tourneau C, Lheureux S, Fanti S, Lopci E.

Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):238-250. doi: 10.1007/s00259-018-4171-4. Epub 2018 Oct 5. Review.

37.

Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes.

Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, Kong G, Kumar AR, Thang SP, Eu P, Scalzo M, Murphy D, Williams S, Hicks RJ, Hofman MS.

J Nucl Med. 2019 Apr;60(4):517-523. doi: 10.2967/jnumed.118.219352. Epub 2018 Oct 5.

PMID:
30291192
38.

A pilot study of cardiopulmonary exercise testing and cardiac stress positron emission tomography before major non-cardiac surgery.

Ferguson MT, Hofman MS, Ismail H, Melville A, Yap KSK, Hicks RJ, Wright S, Riedel B.

Anaesthesia. 2018 Dec;73(12):1524-1530. doi: 10.1111/anae.14447. Epub 2018 Oct 3.

PMID:
30284241
39.
40.

Supranutritional Sodium Selenate Supplementation Delivers Selenium to the Central Nervous System: Results from a Randomized Controlled Pilot Trial in Alzheimer's Disease.

Cardoso BR, Roberts BR, Malpas CB, Vivash L, Genc S, Saling MM, Desmond P, Steward C, Hicks RJ, Callahan J, Brodtmann A, Collins S, Macfarlane S, Corcoran NM, Hovens CM, Velakoulis D, O'Brien TJ, Hare DJ, Bush AI.

Neurotherapeutics. 2019 Jan;16(1):192-202. doi: 10.1007/s13311-018-0662-z.

PMID:
30215171
41.

Bayesian approach to determining penetrance of pathogenic SDH variants.

Benn DE, Zhu Y, Andrews KA, Wilding M, Duncan EL, Dwight T, Tothill RW, Burgess J, Crook A, Gill AJ, Hicks RJ, Kim E, Luxford C, Marfan H, Richardson AL, Robinson B, Schlosberg A, Susman R, Tacon L, Trainer A, Tucker K, Maher ER, Field M, Clifton-Bligh RJ.

J Med Genet. 2018 Nov;55(11):729-734. doi: 10.1136/jmedgenet-2018-105427. Epub 2018 Sep 10.

42.

A new model for training in hybrid imaging.

Hicks RJ, Freudenberg L, Beyer T.

Lancet Oncol. 2018 Sep;19(9):1152-1154. doi: 10.1016/S1470-2045(18)30482-0. No abstract available.

PMID:
30191837
43.

[177Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer - Author's reply.

Hofman MS, Violet J, Hicks RJ, Sandhu S.

Lancet Oncol. 2018 Aug;19(8):e373. doi: 10.1016/S1470-2045(18)30534-5. No abstract available.

PMID:
30102223
44.

Outcome of patients with early-stage follicular lymphoma staged with 18F-Fluorodeoxyglucose (FDG) positron emission tomography (PET) and treated with radiotherapy alone.

Ng SP, Khor R, Bressel M, MacManus M, Seymour JF, Hicks RJ, Wirth A.

Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):80-86. doi: 10.1007/s00259-018-4112-2. Epub 2018 Aug 7.

PMID:
30083824
45.

Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma.

Fan K, Ritter C, Nghiem P, Blom A, Verhaegen ME, Dlugosz A, Ødum N, Woetmann A, Tothill RW, Hicks RJ, Sand M, Schrama D, Schadendorf D, Ugurel S, Becker JC.

Clin Cancer Res. 2018 Dec 1;24(23):5873-5882. doi: 10.1158/1078-0432.CCR-18-1184. Epub 2018 Jul 30.

PMID:
30061360
46.

What 18F-FDG PET Response-Assessment Method Best Predicts Survival After Curative-Intent Chemoradiation in Non-Small Cell Lung Cancer: EORTC, PERCIST, Peter Mac Criteria, or Deauville Criteria?

Turgeon GA, Iravani A, Akhurst T, Beaulieu A, Callahan JW, Bressel M, Cole AJ, Everitt SJ, Siva S, Hicks RJ, Ball DL, Mac Manus MP.

J Nucl Med. 2019 Mar;60(3):328-334. doi: 10.2967/jnumed.118.214148. Epub 2018 Jul 20.

PMID:
30030343
47.

Deep Learning Renal Segmentation for Fully Automated Radiation Dose Estimation in Unsealed Source Therapy.

Jackson P, Hardcastle N, Dawe N, Kron T, Hofman MS, Hicks RJ.

Front Oncol. 2018 Jun 14;8:215. doi: 10.3389/fonc.2018.00215. eCollection 2018.

48.

FDG PET/CT imaging in detecting and guiding management of invasive fungal infections: a retrospective comparison to conventional CT imaging.

Douglas AP, Thursky KA, Worth LJ, Drummond E, Hogg A, Hicks RJ, Slavin MA.

Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):166-173. doi: 10.1007/s00259-018-4062-8. Epub 2018 Jun 7.

PMID:
29882160
49.

FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC.

Spigel DR, Chaft JE, Gettinger S, Chao BH, Dirix L, Schmid P, Chow LQM, Hicks RJ, Leon L, Fredrickson J, Kowanetz M, Sandler A, Funke R, Rizvi NA.

J Thorac Oncol. 2018 Nov;13(11):1733-1742. doi: 10.1016/j.jtho.2018.05.004.

PMID:
29775807
50.

[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.

Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, Eu P, Jackson P, Scalzo M, Williams SG, Sandhu S.

Lancet Oncol. 2018 Jun;19(6):825-833. doi: 10.1016/S1470-2045(18)30198-0. Epub 2018 May 8.

PMID:
29752180

Supplemental Content

Loading ...
Support Center